LA JOLLA, Calif., July 12 /PRNewswire/ -- Advanced Tissue Sciences, Inc.
(Nasdaq: ATIS) today reported that it has filed a registration statement with
the Securities and Exchange Commission (SEC) for an offering of 5,000,000
shares of Common Stock. The Common Stock is being offered directly by the
Company.
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective. This announcement
shall not constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state in which such
offer, solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.
Advanced Tissue Sciences is a tissue engineering company utilizing its
proprietary core technology to develop and manufacture human-based tissue
products for tissue repair and transplantation. The Company has two joint
ventures with Smith & Nephew. The first covers the application of Advanced
Tissue Sciences' tissue engineering technology for skin wounds and includes
Dermagraft(R) for the treatment of diabetic foot ulcers, TransCyte(TM) for the
temporary covering of second and third-degree burns and future developments
for venous ulcers, pressure ulcers, burns and other non-aesthetic wound care
treatments. The second joint venture is developing tissue-engineered
orthopedic cartilage, initially focusing on the repair of cartilage in knee
joints. The Company also has a strategic alliance with INAMED Corporation for
the development and marketing of several of Advanced Tissue Sciences'
human-based, tissue-engineered products for aesthetic and certain
reconstructive applications. The Company is also developing products for
cardiovascular applications.
The discussion contained in this press release relating to research,
development, or commercialization of the Company's products involves certain
risks and uncertainties. No assurances can be given that the Company will
successfully develop any such products, complete clinical trials, obtain
regulatory approval (or that any such approval will be obtained on a timely
basis), be able to manufacture or successfully commercialize such products.
These and other risks are detailed in publicly available filings with the
Securities and Exchange Commission such as the Company's Annual Report on Form
10-K for the year ended December 31, 1998 and the Registration Statement on
Form S-3 filed on July 12, 1999. Actual results may differ materially from
those currently anticipated as a result of such risks.
SOURCE Advanced Tissue Sciences, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/532975.html or fax,
800-758-5804, ext. 532975
CONTACT:
Cheryl B. Monblatt, Director, Corporate
Communications and Investor Relations of Advanced Tissue
Sciences, Inc., 858-713-7802
|
